Last updated: September 7, 2026
Coagulation factor Xa (recombinant), inactivated-zhzo, marketed as Andexxa in the United States, is a recombinant reversal agent for life-threatening or uncontrolled bleeding caused by apixaban and rivaroxaban. Its commercial value depends on hospital adoption, emergency-use protocols, payer coverage, clinical confidence, and competition from lower-cost prothrombin complex concentrates. AstraZeneca owns the product following its acquisition of Portola Pharmaceuticals.
Andexxa has regulatory differentiation as a targeted antidote, but its market has remained constrained by high acquisition cost, limited emergency use, thrombotic-risk concerns, and inconsistent hospital formulary placement.
What is coagulation factor Xa (recombinant), inactivated-zhzo?
Coagulation factor Xa (recombinant), inactivated-zhzo is an engineered, catalytically inactive form of human factor Xa. It binds circulating factor Xa inhibitors and reduces their anticoagulant effect without initiating coagulation itself.
| Attribute |
Product detail |
| Brand |
Andexxa |
| Nonproprietary name |
Coagulation factor Xa (recombinant), inactivated-zhzo |
| U.S. sponsor |
AstraZeneca |
| Original developer |
Portola Pharmaceuticals |
| FDA application |
Biologics License Application 125622 |
| FDA approval |
May 3, 2018 |
| Indications |
Reversal of anticoagulation from apixaban or rivaroxaban in life-threatening or uncontrolled bleeding |
| Administration |
Intravenous bolus followed by continuous infusion |
| Primary setting |
Hospital emergency departments, intensive-care units, operating rooms |
| Product type |
Recombinant biologic antidote |
| Main alternatives |
Four-factor PCC, activated PCC, supportive care, drug-specific management |
| Direct approved competitor |
None for factor Xa inhibitor reversal in the United States as of the cited period |
The FDA initially granted accelerated approval based on reduction in anti-factor Xa activity. Clinical benefit was supported by subsequent clinical evidence and postmarketing requirements, including randomized evaluation against usual care.[1,2]
How large is the Andexxa market?
The addressable market consists of emergency bleeding episodes in patients taking direct oral anticoagulants, primarily apixaban and rivaroxaban. The opportunity is narrower than total direct oral anticoagulant use because only a minority of treated patients experience major bleeding requiring reversal.
Market demand is driven by four variables:
- Growth in apixaban and rivaroxaban use.
- The number of intracranial, gastrointestinal, and other life-threatening bleeds.
- Hospital protocols that require a targeted antidote.
- Reimbursement sufficient to offset the product’s acquisition cost.
Andexxa is generally used selectively rather than routinely. Hospitals often reserve it for intracranial hemorrhage, urgent surgery, or bleeding with documented recent factor Xa inhibitor exposure.
What clinical evidence supports Andexxa demand?
The ANNEXA-4 study reported excellent or good hemostatic efficacy in 82% of evaluable patients after treatment with andexanet alfa, with substantial reduction in anti-factor Xa activity.[3] The single-arm design limited direct comparison with alternative reversal strategies.
The ANNEXA-I randomized trial provided stronger comparative evidence in patients with intracerebral hemorrhage. Andexanet produced better control of hematoma expansion or effective hemostasis than usual care, but it also produced more thrombotic events.[4]
| Evidence factor |
Commercial effect |
| Targeted reversal of apixaban and rivaroxaban |
Supports premium pricing |
| Rapid anti-factor Xa reduction |
Supports emergency-department use |
| Better hemostatic efficacy in ANNEXA-I |
Improves formulary justification |
| Higher thrombotic-event rate |
Raises clinical and budget concerns |
| No direct approval for edoxaban or betrixaban reversal |
Limits total addressable market |
| High treatment cost |
Encourages PCC substitution |
What is the financial trajectory for Andexxa?
AstraZeneca does not generally report Andexxa as a standalone segment in the same level of detail as its largest oncology, respiratory, and rare-disease products. Public company reporting places Andexxa within broader product-sales disclosures, limiting precise assessment of product-level profitability.
The commercial trajectory has been positive but modest relative to AstraZeneca’s portfolio. Product sales benefited from the growth of factor Xa inhibitor use and broader hospital awareness, but uptake has been restrained by treatment cost and competing reversal protocols.
Andexxa commercial trajectory
| Period |
Financial and commercial direction |
| 2018 |
U.S. launch after accelerated FDA approval |
| 2019 |
Early adoption concentrated in major academic and trauma centers |
| 2020 |
AstraZeneca acquired Portola, consolidating global ownership |
| 2021-2022 |
Increased formulary penetration, but use remained episodic |
| 2023-2024 |
Demand supported by broader clinical evidence and continued direct oral anticoagulant growth |
| Forward outlook |
Moderate revenue growth, with margin pressure from evidence requirements and hospital price sensitivity |
The acquisition of Portola by AstraZeneca closed in June 2020 for approximately $18 per share, implying an equity value of about $1.7 billion and an enterprise value of approximately $1.1 billion after adjustment for Portola’s cash position.[5] The transaction transferred Andexxa, Portola’s principal commercial asset, to AstraZeneca’s Alexion organization.
What drives Andexxa revenue?
Andexxa revenue is sensitive to treatment volume rather than chronic prescription volume. It is administered only when a qualifying bleeding event occurs. The product therefore has a low-frequency, high-value revenue model.
Revenue drivers include:
- Rising prevalence of atrial fibrillation and venous thromboembolism.
- Greater use of apixaban and rivaroxaban.
- More aggressive emergency reversal protocols.
- Inclusion in stroke-center and trauma-center formularies.
- Improved reimbursement under inpatient payment systems.
- Clinical preference for targeted reversal over nonspecific procoagulant therapy.
Revenue constraints include:
- Use of four-factor PCC at materially lower cost.
- Inventory expiration and hospital budget controls.
- Difficulty confirming the last anticoagulant dose.
- Thrombotic-risk concerns.
- Reimbursement disputes and variable payer policies.
- Limited use outside major hospitals.
What is the FDA regulatory status of Andexxa?
Andexxa received FDA approval in 2018 under the accelerated approval pathway. The original approval covered patients treated with apixaban or rivaroxaban who had life-threatening or uncontrolled bleeding.
The label includes low-dose and high-dose regimens. Dosing depends on the anticoagulant, dose, and time since the last dose. The product requires reconstitution and intravenous administration, creating operational complexity during emergencies.[1]
Regulatory milestones
| Date |
Milestone |
| 2018 |
FDA accelerated approval |
| 2018 |
U.S. launch by Portola |
| 2020 |
AstraZeneca acquisition of Portola |
| 2023 |
FDA label updated to reflect expanded dosing and clinical information |
| 2024 |
ANNEXA-I results published, strengthening comparative evidence while highlighting thrombotic risk |
Andexxa is a biologic, not a conventional small-molecule drug. The product is regulated under a BLA rather than an NDA. The principal U.S. follow-on pathway is therefore biosimilar approval under the Public Health Service Act, not an Abbreviated New Drug Application.
What patents protect coagulation factor Xa (recombinant), inactivated-zhzo?
The Andexxa intellectual-property estate is expected to include patents covering engineered factor Xa proteins, inactive catalytic-site variants, binding properties, pharmaceutical compositions, and methods of reversing factor Xa inhibitor activity.
Core protection is likely divided into four categories:
| Patent category |
Commercial relevance |
| Modified factor Xa molecules |
Protects the active biologic construct |
| Catalytically inactive variants |
Protects the nonenzymatic antidote mechanism |
| Formulations and dosing |
Protects product presentation and administration |
| Methods of reversal |
Protects treatment of anticoagulant-associated bleeding |
The commercial patent position is stronger when composition-of-matter claims remain enforceable. Method-of-use claims are more vulnerable to physician-use and induced-infringement challenges, while formulation claims generally provide narrower fallback protection.
What is the Orange Book status of Andexxa?
Andexxa is a biologic approved under a BLA and is not treated like a standard small-molecule product with a conventional Orange Book patent-and-exclusivity profile. Patent information for biologics is assessed through the Purple Book framework and related FDA regulatory records rather than relying solely on Orange Book listings.[6]
The product’s regulatory exclusivity and patent protection should therefore be analyzed separately:
- FDA biologic exclusivity protects the reference product for a statutory period.
- Patents may extend beyond regulatory exclusivity.
- A biosimilar applicant could challenge patent barriers before commercial launch.
- Patent expiration depends on the specific claim set, terminal disclaimers, patent-term adjustment, and any regulatory patent-term extension.
Public patent databases identify Portola and related entities as applicants or assignees for factor Xa antidote technology. The estate’s practical strength depends on whether broad molecule claims survive validity challenges and whether later patents cover commercially necessary formulations or dosing methods.
When does Andexxa lose exclusivity?
Andexxa’s earliest regulatory exclusivity and patent expiry dates are not interchangeable. FDA reference-product exclusivity limits biosimilar approval timing, while patents may delay launch after regulatory exclusivity expires.
For a biologic approved in 2018, the reference-product exclusivity period generally reaches 12 years from first licensure, subject to the specific statutory treatment of the application and any prior-licensure issues. That places the principal U.S. biosimilar approval barrier around 2030, although patent litigation could alter the effective launch date.[7]
Exclusivity risk timeline
| Protection |
Approximate implication |
| BLA reference-product exclusivity |
Extends into approximately 2030 |
| Composition patents |
May extend into the late 2020s or around 2030, depending on patent family |
| Formulation and method patents |
Could create later but narrower barriers |
| Biosimilar litigation |
Could begin before statutory exclusivity expires |
| Commercial launch risk |
Depends on patent settlements and court outcomes |
No approved biosimilar to Andexxa was identified in the cited FDA regulatory materials. Biosimilar development is technically difficult because the product is a recombinant protein with a complex mechanism, emergency-use formulation, and limited treatment volume.
Which companies are challenging Andexxa?
No direct FDA-approved biosimilar competitor has displaced Andexxa in the United States. Competitive pressure comes mainly from alternative clinical strategies.
Four-factor PCC
Four-factor PCC is the most important commercial substitute. It is widely available, familiar to hospitals, faster to deploy in some institutions, and usually less expensive. Its use for factor Xa inhibitor reversal is generally based on clinical practice, guidelines, institutional protocols, or observational evidence rather than the same type of targeted mechanism as Andexxa.
Ciraparantag
Ciraparantag is an investigational synthetic reversal agent designed to bind several anticoagulants. It has not established a U.S. commercial position comparable to Andexxa. Development, regulatory approval, clinical differentiation, and pricing remain material hurdles.
Idarucizumab
Idarucizumab is approved for reversal of dabigatran, not apixaban or rivaroxaban. It competes for hospital antidote budgets and emergency-reversal protocols but is not a direct substitute for Andexxa’s approved indication.[8]
What patent litigation and Paragraph IV risks affect Andexxa?
Paragraph IV litigation is a Hatch-Waxman mechanism for small-molecule ANDA products. It is not the standard pathway for a biologic BLA product such as Andexxa.
The principal challenge mechanisms are:
- Biosimilar patent litigation under the Biologics Price Competition and Innovation Act.
- Declaratory-judgment actions involving patent validity or enforceability.
- Inter partes review of issued patents.
- Patent-licensing settlements.
- Regulatory challenges to scope of the reference product’s approved indication.
A biosimilar applicant could challenge molecule, formulation, manufacturing, or method claims. The strongest litigation risk would arise if a competitor can market a highly similar recombinant factor Xa product after reference-product exclusivity while avoiding enforceable composition claims.
How strong is the Andexxa patent estate?
The estate has meaningful strategic value because the product combines a biologic molecule, engineered catalytic inactivity, a defined anticoagulant-binding mechanism, and emergency-use formulations. Composition claims are potentially valuable if they cover the precise clinically used construct.
The estate is less secure where protection depends on:
- Narrow sequence limitations.
- Functional binding claims.
- Treatment-method claims.
- Specific infusion regimens.
- Formulation claims that can be designed around.
- Manufacturing steps that are not essential to the final product.
Manufacturing remains a practical barrier even after patent expiry. A biosimilar developer must reproduce protein quality, inactive enzyme characteristics, aggregation profile, stability, potency, and batch consistency. These barriers may delay entry beyond the earliest legally available date.
What is the generic or biosimilar launch risk?
Near-term generic launch risk is low because Andexxa is a biologic. Medium-term biosimilar risk is real but limited by market size and development economics.
A biosimilar entrant would face:
- Clinical comparability requirements.
- Complex analytical characterization.
- Emergency-use manufacturing and supply requirements.
- Hospital contracting pressure.
- A concentrated customer base.
- The need to establish interchangeability or secure protocol adoption.
- Potential patent litigation by AstraZeneca.
The first entrant could compete aggressively on price, but the product’s episodic use and hospital inventory requirements may limit the number of viable competitors.
How does Andexxa compare with PCC and idarucizumab?
| Factor |
Andexxa |
Four-factor PCC |
Idarucizumab |
| Target |
Apixaban and rivaroxaban |
Broad procoagulant replacement |
Dabigatran |
| Mechanism |
Specific factor Xa inhibitor sequestration |
Replaces clotting factors |
Specific antibody fragment |
| FDA indication |
Approved for selected factor Xa inhibitor bleeding |
Not equivalent targeted approval for this use |
Approved for dabigatran reversal |
| Cost profile |
High |
Generally lower |
High |
| Evidence base |
Randomized evidence available |
Extensive clinical use, less targeted evidence |
Strong drug-specific evidence |
| Main risk |
Thrombosis and cost |
Thrombosis and nonspecific reversal |
Thrombosis and limited target population |
| Main commercial setting |
Major hospitals and stroke centers |
Broad hospital use |
Dabigatran-treated patients |
What is the outlook for Andexxa revenue?
The base-case outlook is moderate growth followed by increasing price pressure. Demand should track the installed population of apixaban and rivaroxaban users, but product utilization will remain constrained by treatment cost and competition from PCC.
The most favorable commercial scenario would involve:
- Continued growth in factor Xa inhibitor prescriptions.
- Strong adoption of ANNEXA-I findings.
- Payer recognition of targeted reversal value.
- Greater use in intracranial hemorrhage.
- Stable safety interpretation.
- Limited biosimilar competition before 2030.
The downside scenario includes:
- Wider PCC use driven by hospital budget pressure.
- Thrombotic-risk concerns after randomized evidence.
- Restrictive payer policies.
- A biosimilar entrant with aggressive pricing.
- Hospital protocols requiring PCC before Andexxa authorization.
Key Takeaways
- Andexxa is AstraZeneca’s recombinant factor Xa inhibitor reversal biologic for apixaban- and rivaroxaban-associated life-threatening bleeding.
- Its market is hospital-based, episodic, and high value per treatment rather than prescription-volume driven.
- Revenue growth benefits from direct oral anticoagulant expansion but is limited by price, formulary controls, and PCC competition.
- ANNEXA-I improved the product’s comparative evidence while confirming concern about thrombotic events.
- Andexxa is regulated under a BLA, so biosimilar and Purple Book analysis is more relevant than a conventional Orange Book or Paragraph IV analysis.
- Reference-product exclusivity is expected to extend to approximately 2030, with patent barriers potentially extending or narrowing the effective launch window.
- The strongest intellectual-property protection is likely to come from composition claims covering the engineered inactive factor Xa molecule.
- Manufacturing complexity and clinical comparability requirements may slow biosimilar entry even after legal exclusivity expires.
FAQs
Is Andexxa a blood thinner?
No. Andexxa is a reversal agent that binds factor Xa inhibitors and reduces their anticoagulant effect.
Is Andexxa approved for edoxaban reversal?
The U.S. indication is for reversal of apixaban and rivaroxaban in life-threatening or uncontrolled bleeding. It is not broadly approved for edoxaban reversal.
Is Andexxa interchangeable with four-factor PCC?
No. The products have different mechanisms, regulatory positions, evidence bases, and dosing protocols. Hospitals may use PCC when Andexxa is unavailable, restricted, or considered unsuitable.
Can a biosimilar of Andexxa launch before 2030?
A biosimilar could be developed and seek approval before that date, but statutory reference-product exclusivity and patent litigation could prevent commercial launch until the applicable barriers expire or are resolved.
Why is Andexxa expensive?
The product is a recombinant biologic requiring complex manufacturing, specialized formulation, controlled hospital inventory, and emergency-use distribution. Its pricing also reflects the value assigned to targeted reversal in catastrophic bleeding events.
References
- U.S. Food and Drug Administration. (2018). Andexxa prescribing information: Coagulation factor Xa (recombinant), inactivated-zhzo.
- U.S. Food and Drug Administration. (2023). Andexxa regulatory and labeling information.
- Connolly, S. J., Milling, T. J., Jr., Jr., et al. (2019). Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. New England Journal of Medicine, 380(14), 1326-1335.
- Connolly, S. J., Sharma, M., Cohen, A. T., et al. (2024). Andexanet for factor Xa inhibitor-associated intracerebral hemorrhage. New England Journal of Medicine, 390, 1745-1755.
- AstraZeneca. (2020). AstraZeneca completes acquisition of Alexion Pharmaceuticals and Portola-related assets.
- U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.
- Biologics Price Competition and Innovation Act, 42 U.S.C. § 262.
- U.S. Food and Drug Administration. (2015). Praxbind prescribing information: Idarucizumab.
